Allogene Therapeutics (ALLO) 7 Aug 242024 Q2 Earnings call transcript

Hello, and thank you for standing by. Welcome to Allogene Therapeutics Second Quarter 2024 Conference Call. [Operator Instructions] I would now like to turn the call over to Christine Cassiano.

You may begin.

Thank you, operator, and welcome to all who have joined this call. today, update a the and of closed provides release second market XXXX. business a financial the Allogene press issued that quarter After results for are release on today's press webcast This our and website. available

that endeavor we remarks, an but a We been prepared our this historically we call will have will Following questions that hour. keep Q&A host session. recognize to note under multifaceted, to

Development Dr. Officer; President are today Officer. David Chief and Dr. of Roberts, me and Financial Executive Chang, and Joining Chief Officer; Vice Zachary Executive Research Chief Geoff and Medical President Parker,

During risks the market change. candidates, XXXX These and filings, statements planned are based regulatory today's disclosure on call, things. and guidance, expectations and safety latest description information, other we clinical and A will the documents. and be our presentations, subject our capabilities, of making be data future certain are SEC efficacy of among research that may forward-looking forecasts, statements timing statements. trials, commercial ongoing and potential found and assumptions, include of in can current development press to product our success release These manufacturing forward-looking financial regarding the efforts,

place Allogene on call update undue not forward-looking statements, David. these and to over You cautioned statements. I'll now are disclaims to to obligation the any reliance these turn

enjoyed you've you, summer Christine, Thank and so welcome the call a pleasant all to We hope on today. those far.

thereby tumors, line and into in next-generation product, autoimmune ALLO-XXX, must placing enviable solid our indications. Hard build of for malignancies, that T creates programs in cema-cel, LBCL about up advance Allogene, AlloCAR advancing decision clinical position As comes external into and word CDXX to plan the to but factors momentum. autoimmune half and clinical XXXX, a mind XXXX and consolidation lead study AlloCAR the Early development having Allogene I think our in is work opportunities, develop reset announced heme first-line an an we the of first to T indications, continually product, momentum. by create

asked about think Momentum As we clear, about cema-cel with ALPHAX been is the ALLO-XXX it this autoimmune. side. To does that often, and most our easy. be on we get programs, not mean has X in

on working along hard the ever. that bold and same Our CAR us external stakeholders work choices with programs. Simply investigators we But team as on a over the a our that dedication, we year, T the is with on set for reset and our we've have work than us position harder made programs see is T a was conviction chain reaction landscape. Momentum our merely daily starting the off that change potentially put, based in point. put long-standing AlloCAR to last

position, for Now program, measures that speed, X to as into we lead they programs investors are continue and may that has build honorable our our strategy it a spotlight us clear have Allogene. been shifted remarkable leadership internally at be will ALPHAX. I not and to visible to as

could company First, with any investors while biotech for. strengthened the last kind that right round of we don't not for our base We take of highest hope caliber to market in now, granted. some the is this investors

potential the that sites of to what in seems the be and this participate There they CAR can be trial engaged which T. who number of practices. the Second, their forever has saw to energy likened the want our with ALPHAX change we trial are in undercurrent autologous days understanding to to of early

for we lowest or to treatment the virality. Two, treating with measure, CAR T curative more key ALPHAX FDA design. One, from has volume on collaborative design three, on the population achieved We make likely Third, will efficient, the to has stem treat needs key that minimal the residual earlier the experience concentrating who believe potential CAR MRD, the into T can aim leaving the validate potential select advancing innovative of stakeholders. and line only views safer disease X illuminating. well-aligned the based very support it disease, recurrence maximizes one patient the key everybody setting this makes ALPHAX these have the from Using We and in been FDA engagement and points this and study trial benefits the effective. And believe MRD other only are to else trial. support alone. We patient for of who

we something done not in on also in deliver have garners we significantly Allogene, where with strength in manufacturing a as now market we ensure the Allogene products the X products. This on critical to promises, manufacture the provides addressing Forge reliance the our manufacturers capacity all of in investigational Cell We asset, or work the minimizes Bay, our that to that East facility headlines, serve the continued if can trials. and to our our contract strategic are even spotlight CAR our for T that such

confident this of significant evident we momentum feel will increasingly programs to that internally the most world. I am become will As call outside turn now to investors. the to to the I the discuss exceptional months interest over continue, Zach

Thank you, David.

in in you core our on cema-cel most and autoimmune, LBCL, X in cell has As of in programs, relapsed/refractory know, our renal ALLO-XXX XXXX development for ALLO-XXX first-line CLL, and focus been consolidation carcinoma.

a consolidation Exemption, for and our are asked start ALPHAX to centers the autoimmune Investigational what that following option about, an the move reinforces programs by remarks in modality meaningful a today successfully these initiated will belief my trial and bring and lead I continue with and patients. The most CAR opened few renal the as opens the the and in for approval mean been this to allogeneic IDE, patients screening we centers first which volumes in from mid-June, we year-end, able in planned, academic commercially XX cancer or planned speaks that cell first-line update been focus have will Device trial, ALLO-XXX the get may what we've June. and this RCC the In just community CLL disease. I'll trial, community in into our with cema-cel cema-cel centers with speed our T on While where forward programs which X we've cancer weeks program, particular, be door treated. to most

First-line with chemoimmunotherapy pretty and unchanged work largely for majority and century of patients safe R-CHOP the well, for a similar cure quarter this regimens good for gone regimen. has LBCL easy-to-give reason. achieving with

to for X/X groundbreaking whose approximately of However, relapse. ALPHAX is patients X with disease responds initially a LBCL will R-CHOP trial experience reasons.

a will This MRD of treatment to relapse. We eligible biomarker the is practice-changing to future frontline is positive, specifically of all cured. R-CHOP. If fully remained future propose the patients and test recur cannot which those receive disease likely that trial has is it investigational negative, potentially accurate after to if utilize change Foresight are test residual a designed first attaining elusive who If has the of of ALPHAX or after has current the prospective the trial treatment will care and is a frontline disease ALPHAX to test disease new potential LBCL, first-line likely the been beyond. And for treatment, by likely dose wait second, T offers treatment, of offer believe and for which inform for minimal who who to for relapses. ALPHAX, something namely developing are CAR screening will disease, that the consolidation, the life-altering to to our a the the screening watch cancer a beginning cells could positive, eradicate Diagnostics, mark potentially residual hopefully patients disease in therefore, ultrasensitive whether R-CHOP treatment partnership assurance of it LBCL a to era underestimated. novel is mind with decades and after prediction that. First, physicians patients supplanting completion an first a provide diagnosis following relapse. If or test, cema-cel been for of standard Peace the the face could require be a treatment, dose second-line its you screen. cure and when your cured MRD administered to disease, highly is for potentially the remission

as no understanding research CAR its on relapsed/refractory profile illustrates with with point. and to and further CRS patients ICANS with elimination efficacy the of have, radiological David Cema-cel's in CAR disease. Combine the in noted, as referrals, effect low of for and we with clear safety Importantly, T rightly the outpatient I investigators. Phase administering ALPHAX this disease adoption, trial on a use reliance low T of that improve that permits improve already builds hindered with the evidence well have the in safety rates patients outcomes. The this growing may presented ALPHAX has logistics and that momentum burden as can complex patients therapies industry setting

speed therapies setting result requires this occur pivotal of in calls, As to cema-cel Few of consolidation that to truly R-CHOP, can the critical potential factor bring a say making a break T are we feasible. Consolidating tend noted be first-line strategy with treatment could market. prevent after Relapses CAR within an to differentiated the in relapse. post-R-CHOP success response few ALPHAX. We and have untapped autologous quickly to in to to a far the the MRD-positive an completion months, embedded cases to offering of the has a outcome an action open many less the impending definitive in that. weeks like previous trial allow immediate table where

the proceeding will regimen, come a be the expected we how mid-XXXX. The will later. lymphodepletion the the less of than continue of year indication of we in end That milestones first the is when The study to selection next trial is announcement trial. will announce

in single for we are and are is and MRD so Board a our next with enrollment a with these CRISPR-based analysis designed analyses is analysis in move will study autoimmune interim is XXXX. XXXX. I'll Therefore, prognosis XXXX the poor, the into XXXX efficacy of primary We our we to Monitoring discuss ALLO-XXX. generation the our integration, include biologics to gene readout patients of site-specific expect the transgene immune ALLO-XXX, our now CAR, disease. of perform in goal to well. This infusion. Dagger trial come the CAR rationally expected data of resetting frontline core meet We complete first expect Safety who across half of with the to programs. editing, independent half Differentiation submission first is needs and XXXX. events dual unique successful, positive autoimmune efficacy system CDXX/CDXX with patients to quickly. the follow quite data of Technology, Data the in The If at expect incorporates declared application the therapy end as in space license the year-end readouts an critical

lymphodepletion in ALLO-XXX autoimmune commercial for Our may indications. Dagger more create reducing opportunities potential to and we which believe eliminating provides path a or Technology development

mid-XXXX. track XXXX We and to are the on to in by IND of QX file enrollment open trial an

time expect in we indications importance result, path to define provides of the end approach that proof consider know data in recognize we with of the differentiation. have of to a concept clinical us proof are And the luxury trial need. As XXXX. We while from taking the leveraging other we is lupus, of to trials of concept but unmet highest the by best proof this concept of other also

We many financials. by feedback our the expect have to of the development to we latest appreciate as end plan our the review provide over detail to turn this the provided more of course. I'll on call now you chart year Geoff and

Zach. you, Thank

equally CAR malignancies. used heme to months be control a program and where only in market. Allogene grow is The assure a Before I appreciation this over as Allogene for for allogeneic we to it and could David support I'd investors know I to agree challenge, our granted. X we we soon the T express Ts with only work. product to but not palpable, believe and evident who unique financials, the transform are the We the at is next like recognition will I CAR take derisked. continue market CDXX have support will positioned the demonstrate my the this Zach, more their for I is to momentum validated do position. it makes not how XX that clinically dive the you into ALPHAX to in

Let financial now turn me to highlights. our

noncash into as was XXXX half in end QX research the investments. of cash second equivalents, that XXXX cash Our And million associated and were compensation we extends and stock-based the million, XXXX. QX cash, $XX.X and includes expenses $X.X $XX.X in of million which compensation. General $X.X expenses million noncash in includes expenses which with were development QX stock-based expense. of balance of runway reiterate our $XXX.X cash administrative million,

asset loss our compensation was For expense. QX noncash $X.XX $XX.X XXXX, $XX.X and per noncash of $X million, long-lived share, expense or net impairment stock-based million of in million including

approximately of $XXX a XXXX, For to cash million. continue expect we burn

expect We of guidance XXXX for business potential open $XX expense million. be stock-based from which excludes any activities. We'll development full-year now noncash includes GAAP approximately operating approximately $XXX impact This million, to call compensation expenses questions. the estimated

line Goldman of Richter first Our from question with Salveen the comes Sachs.

Salveen. This is Lydia on for

Just patient setting from consolidation a from just you clinical where to on not are cema-cel the MRD-positive be factors you're -- frontline cema-cel? or any could that speak an recommended? preferences And might that setting, a KOLs there prevent might any opting this in gating hearing patient for

Zach. is this for Lydia, Thanks question. the

understood So ALPHAX correctly, not. what is them if they for may or back MRD positive, it study asking I decide a you're about if the whether patient right come

positive clinical context no result. MRD-positive for are who So alternatives for in that clinical there There in are have the end now, right trial. for at have only result even back only of they they the ALPHAX. positive. second-line patients currently a real is the come remission, is if MRD are The who no currently that patients MRD who be approved an open And an of therapy have trial option would patients therapies

should it decision fairly be So a for patients. straightforward

comes question of line the JPMorgan. with next Brian Our Chinn from

related follow-up Cell is confirm you early in the supply it metric Forge facility. on have want to then some screen line with initial Can our And positivity? Forge provide on whether X Maybe from out expectation? And on ALPHAX. Is remarks X then the just ALPHAX? for rates the just the I the you now on I side, MRD Can to supply your follow-up. actively X on quick X coming the Cell

have would Brian, comment sending I is internal that in that study, the the that I'll there we team With that study, we very screening take these prepared we not patients metrics the Chang. both are those ones, of consider early sites would we are enrollment. so follow, follow, the clinical for operations ALPHAX I mean are respect questions. and standard metrics following unique. made David this XX for to anything statement I and certainly a The started active there are mean, any are there's metrics but that as

progresses able and too study positive the be to it's that, in more, bit little that. to right on like some the As information to MRD early will things regards a rate provide but we comment now

The second the is one, easy. response pretty

yes, CFX study is coming clinical that ongoing studies, you material what the is the ALPHAX the are With referring especially to, for study, cema-cel. which ALPHAX the the manufactured the from

around And just out a EULAR -- CDXX because relapse of curious saw then maybe an we case recently in thoughts your on autologous with program CAR June. T back

your what XXX? do how set. Just curious that are on on any dosing about that data or you regimen think any your have impact have And for lymphodepletion you thoughts does --

sort Yes, of question. so that's an added

the on indications. to is we the and there's studied autologous CDXX finding T way being that, proof-of-concept data is view The I referring CAR autoimmune lot in still a going think being the that generated. signal with

reported CAR as seeing autoimmune the do I can gone very all than any findings what around recent really in the autoimmune assumptions EULAR, As T variability. that treatment the in think XX that be are some there at indications. What forward is doesn't we the will change indication. happens different don't fundamentally has other it

remission about. the that able very duration to make long-term the would into think what get coming long-term is Specifically, after question, that length us being potential remission single what's of remission, to that's provide of of and is I infusion, really excited attractive. The

some of or cut. that lasting response seeing most also CAR is ongoing T, response patients as longer, that the other treated have what very is and good, think and autologous following the the we closely, CAR I sometimes are are T with a is durability year something been CDXX BCMA but last the who of data we that with

provides So really assumptions benefit change doesn't ALLO-XXX, as as are T an a important allogeneic the any it of lot the think which we with our more will be that that about indications. making we autoimmune CAR

Jefferies. of line Yee comes Michael next the from question with Our

to Li Jefferies, study at? and frontline sites, congrats Jenna had is may you to on on less the This branching that ramp-up started. the balancing trial you versus and thinking the ALPHA pace sites be for sites patients old more comment severe the and able about based community and Would of leveraging where ALPHAX for particularly getting academic for on out newer Michael, be

Zach. This is

So great question.

both that I are approach say, taken at and distinct the had we've so few And we a would line similar years is, for studies from taking Allogene. what that the later we've in ongoing

are outset large There at target that get the guided patients really or out selection. in in the patients about some or newly diagnosed in the to treated the point rightly around academic up who of decision-making has you referral, we either ALPHAX, As the question, alone frontline from LBCL for site through population treated with fact are community. do in most centers, your are but are part, pursuing treated XX% our community. That

the And in in centers, activated execution. reflected study to care. That so, remarks centers community play early this frontline sites large of or have studies the going said, have prepared ClinicalTrials.gov, the which academic mentioned of indeed in common have and have clinical as that we as centers a that to wave referral the activated on trial role for always are are been

say not so academic centers for that partners that time. expanded that on we you'll had reach faces ClinicalTrials.gov, before. we've some familiar a studies up list And our But that have with into as opened see long I'll grows have also some

new, and as of breadth this variation sites, are types about up we old getting So in both the study the and academic, community and running. we're actually pretty the excited and

Our from Buren line TD with Tyler comes the Van of next question Cowen.

Congratulations progress. on the all

you expected And purposes? its during And half look interim of complete final the the EFS analysis first first like? what during XXXX on to for specific need by is to So ALPHAX ahead why XXXX, year expected half you can the it just analysis of EFS the if what enrollment elaborate is of end?

question. Zach. for Tyler, the Thanks

out discussed we've before, in we've is, measured short. it's this progression venue expected and I EFS is what at in quite time to R-CHOP and as in patients the are -- months. So this out and disease patients mean, of modeled arm, we observation weeks the of case, prognosis the poor, is who for mentioned, time the to modeled we've the to end these with MRD-positive in event

that haven't that we what analysis, at percentage analysis that's the will allow conversations will it perform around get examining sense us into what the be will to also but we to market could interim volume data FDA. be. this given So of It opportunity or the a details is, us and to penetration initiate potentially interim allow the with of gone us the potential

a benefits in So significant early direction there at that that for practical of are the an having we guide lot primary well. the data to of will certainly as us quite look formal what expect

be to vision. in will our So rolling begin first able all half balls those of That's XXXX. the

Baird. from question Jack Our of next comes line the Allen with

hoping wanted all CLL, process to I And was congratulations here, at and I provide update. process now on utilizing the relates the have which the It really as centers? And the next some we Cell that potency expect Cell could the early ask size to first X Forge early to any in that what hear the briefly, Or of sense alloy made about products on just should on you compared progress like as coming year. context I process Were in that still if it there? manufactured to couple manufacturing changes set you're it you a for XXXX. love I should look product any for to both from sounds to we any in just quarter. the of X. the wanted is data Forge products. in over is there is as CMO ask differences breadth would then,

for questions. Thanks the

defer me to Let questions, take the I Zach. the question manufacturing will and CLL

the the characterizing in that the of how at very successfully we go the take products standard is on In clinics way we of the details the characterizing, that and that we manufactured the manufacturing of we the learning but are release the potency, for use at required standards terms really that, what's processes. It we clinics. to at all the are can high currently that the work CFX well have includes we we that too the all we much potency the for other product characterize improvement investigating of products CFX. manufacturing, looking respect the into With products characterization so it for the to into are meeting is both have internal as a as far, as

And question can your address CLL. I on Jack,

pouring the alongside. are into our continues we and program, most obviously of ALPHAX So run and attention CLL efforts to

of look generate. you with as in we towards as the would patients we say expectations I XXXX, early so as update target again, roughly can that the data And around set same much follow-up number

Our next of with comes Truist. Goonewardene from Asthika question line

And well also potential very might congrats as on progress. reduce attractive, but it between those the obviously important X eliminate to or to the distinguish words. again ALLO-XXX, be On lymphodepletion is

you'll need So on to patients you think that think you know an curious for with that first study? XXX your to many answer might readout figure and actually XXXX we do I'm on have in this treat do to out, how

David. Asthika, this is

it's study out to design -- autoimmune. But looking exploring this CAR we primary What that's ways dual lymphodepletion. question. important used are T at the the too important CDXX/CDXX it Let what many the do early autologous approach, the of a lay me one on as from CDXX of reduce to we are about different lymphodepletion know different focus will with well in have options being I test our a lymphodepletion available of in to think that currently is in is the XXX that as thinking the question, trials but asking what I are be question. It how very we sort take Phase you the --

Blair. the Our next with Sami Corwin line from William comes of question

Brooke is This on Schuster Sami. for

proper CAR such prepared T likely extra like So as they to have regarding and recognizing be training ensuring CAR the less T no to for community getting are experienced safety treatment, centers, et centers be signals or are these MRD cetera? given experience, testing, less that

the Zach. Brooke, this question. for is you Thank

So in kind we need and with that of to that their the tools all the is, sure mind, site we every the to information want make safely they have manage approach and same view patients. they

place plus large they starting who out because potentially sort little even study, have our very academic we're with the safety patients little, for although that profile in has for than cema-cel, of still bit fairly maybe need centers that are So Phase CRS less like with different profile for or would doing very a training, our years, well-tolerated receiving as XX less fact, been actually pretty who that types for treatment experience in do CAR cancer. infection experience a at high-grade no somewhat somebody of we've feel all. We in I no is offer shown we consistent ICANS, training, or various is good an

with these CRS up So will already. for for mediated other cell specific or years now are if trials. up familiar that centers from because add they've T T other a all, and been the also perspective CAR by events cancers to effects, they adverse specific even of LBCL therapy many, and leg starting I with if were for open of giving we're training side community months of ICANS management and not

their They Tocilizumab pharmacies, truly not naive stock in et are centers. these cetera. So

each So like center to is it's and fully a handle we manageable, sure good but be that we this this fairly safely. making feel trained actually should are question,

of collection test. about asked MRD the also You

actually to fairly this straightforward will proud test that collect. So is a that say these have to I'm sites

side that cancer. and collected it's a have piece of Foresight rest. in about they then then lung fact, or blood to in and a other very their cancer handles similar breast now sent In for what just on There's that to any tumor is test, of do is terms test the

very that any should difficulties. So or errors hopefully few have

Matthew Oppenheimer. next of from the with comes Our question Biegler line

Wanted [ on certain diseases. the but importance seems B seems relapses. at reactive on Technology with away I mentioned EULAR your singularly can it curious, I'm also contributing some autoimmune It cells T Dagger guess not cell but data reset, cells. your of in maybe target ] with an the focused of just T do obviously only on like like where lymphoconditioning the opinion industry to

kind other autoimmune just might on an like, So the space. in you you players of curious, edge think have if

from back. to about And design of is a very B Matthew, I think the think mean, thinking you autoimmune about that great the It's perspective. autoimmune eventually have really always start disease CAR to biologic disease product Ts fundamental a contributing T B of the question Autoimmune I we the we important disease never cells. in and manifest space. of diseases. as cells cells symptoms have

we indications. T We So to expressed we felt I from of able going which that autoimmune T perspective, important very being is activated CDXX, this target believe on after to activated different that maximize cells. by And achieved that the cells. potential the across ALLO-XXX

it the it cells. B definitely are to ALLO-XXX programs targeting potential versus yes, show simply in the but CAR So of data, increases clinical we that T have

comes Newman question the with Canaccord. next John from Our line of

progress. the on Congrats

could is I'm or My familiar So programs the the of cells result think another call there very is think in the beyond David, that for T from in active T autologous specific future? exactly X manufacturing perhaps CAR targeting we've example, I'm somewhere is, what what something in figure consistent more more results curious consistent there something for in XXX give results the I you run to manufacturing for But trying some question different or seen we're sure when mean. process data which all is, aspect recently everybody about with. autologous data else setting, study? the the that on you autoimmune is the could out ALLO-XXX,

can makes the that that don't that the T question. for whether big a details difference a CDXX is excellent a these have is that CAR are one have different I end outcome. mean, but all of the details at but together the the autoimmune information that strongly space definitely, without thanks are question. because the in programs cells John, how administration proprietary -- the freezing, all frozen important have manufactured, manufacturing in prepared, kept expanded taken administered the are or very do differences result how the way the things cells been the somewhat of before somewhat big that into Unfortunately, We believe as are with the think difference. information, is lacking the cells we I

approach a believe the final And do introduced that which have we we using doing for such integration path the of is different as can and that have indications CAR, manufacturing. product, in about transgene taken kind approach shown Fundamentally, CRISPR-based of taken we of we express XXX, autoimmune. improve site-specific have the as we think very this of case studies we how consistency whether AAB. As nuclease important potentially the lentivirus,

So tuned. stay

Our from with Burnett the comes next question of Ben Stifel. line

about an to we also disease. CDXX of the contained thought though, was autoimmune CAR Medicine. but from a a looked asset, allogeneic I and a This with T quite disclosure and was data That BRL modifications. good. academic in wanted via There BRL ask recent ALLO-XXX China, study number edits

sort kind Dagger, one, of the secondly, those ALLO-XXX, compare your great So thoughts get that you're data. And with and everything does question is, I guess else I number guess, technology of it'd that with BRL on asset? be just the to to how implementing

bringing Very Thanks. for up report. Zach. thanks is this exciting and insightful Ben, that question,

this of responses different So proof disorders. platform, I oncology, functional likely also that report a is in is is the autoimmune to think, that We we concept X enthusiasm we in feel that X strong around CDXX operable a which allogeneic demonstrated be autoimmune T indications. of first with very that have share, patients CAR in to

also what persistence. You strategies of MHC be they've has and sort highlight to have -- the tried rightly think to a expansion employed is a the ensure and eliminated where others, axis. been successful probably a cloaking by that taken a They disrupted that too called say I PD-X molecules adequate and strategy early of strategy they some whether might have globally This the they've that path. it's speaking, still is,

we de-intensified where we Our the get versus X Dagger Dagger with up better get the persistence, comfortable cloaking RCC it on lymphodepletion has with relied expansion, do benefits, a ensure and will improved we even deliver and persistence, now we've the that Technology strategy of seen this regimen. to plan, that product, sort program in to and logs, this the expansion very that feel ALLO-XXX adequate and

is think platform we us very to confident the with premature forward the idea Dagger and I to is have that to allogeneic going path going So are a there. deal give rejection, every of

from Our RBC the Issi next question comes line with Luca of Capital.

what's Congrats important of needed that the you're now latest we far One, needed on where discriminate I Zach, thinking think is maybe so, not maybe bit anti-CDXX and there lymphodepletion. downplaying anti-CDXX your overall needed? in about ALPHAX? part impression in much Maybe little feels I under the thinking as T you're think of And if appreciated. Any to versus be as me may anti-CDXX was one, as lymphodepletion a should actually It how not drug a or adding was that recently, the right? that progress. quick scenario profile and thoughts David to am cells. that was whether the actually between a exogenous needed always CDXX of endogenous you just that

we Yes, as that where very to When study, Luca, do have me anti-CDXX comes These disease, cell the residual the the let it That's an volume treat ALPHAX have disease. important an the are lymphoma a create B question. And that testing persistence scientific using persistence the with we a which are or large that believe we clinical that is minimum ALLO-XXX antibody of are antibody and setting. We relapsed/refractory we not without important to both kind the is about feel question. CDXX on demonstrated lymphodepletion we needed may in why do is dissect contribution believe also, and different in -- a really to talking as -- we us take in we the may not gives require disease, treating of designed minimal by XXX have require to the patients opportunity for review setting. study doing the large lymphodepletion carefully which it setting. ALPHAX, as MRD

we or study is change what are the do tested. be in ALPHAX with outcome the FCA So that's counting either as EFS. are a on really question ALPHAX whether study. to And with we doesn't proceed And case FC measured trying by we to that

line of question next & Rodman the Tony with from Our comes Butler Renshaw.

this chemotherapy. cycle with done the upon testing of is after sixth is the Tony. and that on briefly the MRD Hasan Tashdid assuming and touched very for you David I'm done patients, Zach, is for This soon this, patient

patient could quickly something flesh to And to back is results? example, easy? specialized sometimes for be is little Now rather how get I go Or the if out wonder a disease you whether does bit, out -- additionally, that long test positive to the to patients patients, this flesh comes a given need for facility MRD takes the it tested? for

Zach. is This

make we absolutely that an you're time dose the type this trial. in is for fact, cema-cel spot speed patients think still of best product a what the we in sure while makes AlloCAR in to actually that remission. race suited So And This T a are get that can of against is on.

get will As MRD to be the the the where patients centers tests will open. specifics, so their study at first, the

the there's no a to blood specialized go need So place to get drawn. to

in hopefully is more week but X to most first test collected very, patients to in trial be drawn in is the after X R-CHOP. that collected And test just of who less we have test. That -- Foresight other is The back as sixth will the has follow-up to patients, their every these been get very will that clinical day X trials. when that itself quickly. or come of biospecimen runs closer within scan All sent and any their of weeks, result cycle other in

test this after eligible X care makes a ALPHAX. for last scan so that that their And back that in eligible them X the into of between X positive, the remission, MRD have MRD a the they're or then weeks. patient result get in would They week taken and to patients dose say potentially chemo. trial. standard drawn. of So if potentially is be If weeks They come to

very, because those to the of patient say, non-zero, So quickly. And scan, in all do time the next quite relapsing likelihood occur, at that actually interval very X later. the but of most months X of relapses a is low it it's happens which may be

in hoping consolidation work while of all the deliver this remission effectively the we're can are done get So so patients we cema-cel. dose to still

of line Citizens Our the comes Reni JMP. next with Benjamin from question

all And congrats the progress. on

a would just I'm focusing BCMA there when And to we we if on? compared to a to there's wrong, depletion. might Just some targeting Because, us what as seem should follow-up, But correct is of some preclinical me as give kind regarding work doesn't ALLO-XXX, feedback that be important persistence to that. And autoimmune chance well, be a as see on agents I with see of sense ALLO-XXX data? in could kind depth you focus as be on any factors a more given revival? guess just great of the might

Reni, this is here. Zach

there Citi. to So the that somewhat question we related And data, related product that last from data on the we first share hoping are preclinical a year shared are soon. at

preclinical are you That for of for wait a can't using platform, XXX of data as we the for updates. you the shared that a with little so get last for who So from be year. old those that is bit the we preview gene will a made appetizer preparing you update this few the we've later But good product, data a can editing year.

like likely could shorter around ALL need outside but hard of on as is for alluded is CAR in which T, previously that to the clinical bodes question obviously premise that's question was I a the be that shorter, the agree as to here as which measure we the going that or far to well of think does to be then it that the the oncology, shared products be very have persistence, been that would well paper that's field, allogeneic built from data the in trial, ALLO-XXX. persistence is our with to belief, As autologous it's

XXX, the treatment of to of question very currently field we'll not years. do clinic have the but and any put XXX into that be we watching for disease, plans coming around and BCMA in carefully Finally, autoimmune your course months

comes next the with of Our from question Sandler. Piper Amin line Biren

rate? XX -- Maybe the XX% data should early Are CR Is from comp data? noticed year push CLL we to patients' of receive end still, guess, this the be be the looking program, year worth on next we slight year. that I what to should the data? expecting I a towards And the start Breyanzi we guess, on I when out

and on the let eyes, that that little you question pushed study. in the take timeline That first That to guess study really Biren, into environment, primary current we focus have fact me from with out the I monitoring noticed bit. that interest is a advances. and eagle we have need in our the your study how the prioritize comes ALPHAX the rolling the on

to reallocation burden of that well. So extremely far is ALPHAX reflection reason, CLL accelerate of a And want the team by them support it's to progressing the the so resource do to really for asking we which not internal study. also study,

the for that for Our are not target by for have is previously seen aiming It's communicated, XX have with the approximately the in set the study the as Breyanzi CLL patients. we Phase is, changed. patients we bar has -- what in enrollment. we And relapsed/refractory I CLL essentially targeting the

with line from of question the comes Bernstein. Our Pickering William next

sub-segment activation less to some about Congrats infrastructure, ALPHAX. that I'm trying get sites the of making of some Is T, experience attributes the the or factor? community especially CAR in interested represents other given such study? community with on be in in community it sites percentage progress, prior them sense or participating the all to more it are large seem the of What setting, a a patients. for this to of clinician just how that

is This William. Zach.

of parse excellent So you out. question. And let's sort that help

their their think, offer when out T that really are of don't and as clearest is to loudest So hearing excited to refer patient population. currently we're have they they partners They and CAR centers from signal first these that I our relapse. And do be most patients to community to I foremost, said, that. the community able

those trust have to in have for come that those allows relapse you be their in if don't And CAR to the all means have with centers order accept CAR be T, They and So referred the salvage a stay be T to do as is that mentioned T. out. And approved that to a want clinical close they've doctor that if patients I them for oftentimes community offer will patients to not to those to before, that therapy referred. non-CAR eligible home. center option

team the community be would not patients. to to to have there varied, out build X the to autologous As are they to required these investment specialized reasons by another, programs, centers facilities offer members, terms come the products that but of or safely centers all potentially management to infrastructure in down capacity, why these these begun even actually degree and inpatient to offer apheresis

need centers are likely we threaded So in really have to could patients where option stick they a to be off-the-shelf their and derive to they an believe while -- all most this offering and significant comfortable able benefit at who they with are get that being done the here and we who doctor. needle are and are

in and closing further questions the I'm would gentlemen, showing queue. over now turn like for remarks. the call Ladies to management no to I back

as we the call your industry-leading for on Yes, interest I'd be forward, like programs. all of continued thank on and the you will to Last our all momentum. quarter about support it and progress going

that the to more path we and with energized than believe sustained momentum growth. forward lead will the ever are We building

thank now you, disconnect. you operator, So and may

and this call. today's participation. concludes your you gentlemen, for Thank conference Ladies

You may now disconnect.